000150524 001__ 150524
000150524 005__ 20250319143309.0
000150524 0247_ $$2doi$$a10.1016/j.ijpharm.2025.125196
000150524 0248_ $$2sideral$$a142584
000150524 037__ $$aART-2025-142584
000150524 041__ $$aeng
000150524 100__ $$aSantos-Vizcaino, Edorta
000150524 245__ $$aGenipin-crosslinked double PLL membranes overcome the strength-diffusion trade-off in cell encapsulation without compromising biocompatibility
000150524 260__ $$c2025
000150524 5060_ $$aAccess copy available to the general public$$fUnrestricted
000150524 5203_ $$aCell microencapsulation technologies allow non-autologous implantation of therapeutic cells for sustained drug delivery purposes. The perm-selective membrane of these systems provides resistance to rupture, stablishes the upper molecular weight limit in bidirectional diffusion of molecules, and affects biocompatibility. Thus, despite being a decisive factor to succeed in terms of biosafety and therapeutic efficacy, little progress has been made in its optimization so far. Here we show that, compared to other usually used coating designs, genipin-crosslinked double poly-L-lysine (GDP) membranes are able to simultaneously improve mechanical and mass-transport properties of the microcapsules, without causing any significant increase in the foreign body response when implanted in vivo. In particular, we show that GDP membranes confer capsular integrity under high pressures, both internal and external. Furthermore, this membrane design allows for more efficient bidirectional diffusion of molecules in the 20–40 kDa range while preserving the molecular weight cut-off required for exerting an effective immunobarrier. These findings may also be useful for optimizing the membrane characteristics of multiple drug delivery systems.
000150524 540__ $$9info:eu-repo/semantics/embargoedAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000150524 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000150524 700__ $$aVirumbrales-Muñoz, María
000150524 700__ $$aGonzalez-Pujana, Ainhoa
000150524 700__ $$aLuker, Gary D.
000150524 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, Ignacio$$uUniversidad de Zaragoza
000150524 700__ $$aHernandez, Rosa Maria
000150524 700__ $$aPedraz, Jose Luis
000150524 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000150524 773__ $$g670 (2025), 125196 [11 pp.]$$pInt. j. pharm.$$tInternational Journal of Pharmaceutics$$x0378-5173
000150524 8564_ $$s1044836$$uhttps://zaguan.unizar.es/record/150524/files/texto_completo.pdf$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-01-10
000150524 8564_ $$s1360752$$uhttps://zaguan.unizar.es/record/150524/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-01-10
000150524 909CO $$ooai:zaguan.unizar.es:150524$$particulos$$pdriver
000150524 951__ $$a2025-03-19-14:32:24
000150524 980__ $$aARTICLE